AR045263A1 - Metodo, kit y composicion farmaceutica para tratar infecciones virales - Google Patents
Metodo, kit y composicion farmaceutica para tratar infecciones viralesInfo
- Publication number
- AR045263A1 AR045263A1 ARP040102894A ARP040102894A AR045263A1 AR 045263 A1 AR045263 A1 AR 045263A1 AR P040102894 A ARP040102894 A AR P040102894A AR P040102894 A ARP040102894 A AR P040102894A AR 045263 A1 AR045263 A1 AR 045263A1
- Authority
- AR
- Argentina
- Prior art keywords
- ribavirin
- interferon
- antioxidant
- protective agent
- membrane protective
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 10
- 229960000329 ribavirin Drugs 0.000 abstract 10
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 10
- 102000014150 Interferons Human genes 0.000 abstract 8
- 108010050904 Interferons Proteins 0.000 abstract 8
- 229940079322 interferon Drugs 0.000 abstract 8
- 239000003963 antioxidant agent Substances 0.000 abstract 6
- 230000003078 antioxidant effect Effects 0.000 abstract 6
- 239000012528 membrane Substances 0.000 abstract 6
- 239000003223 protective agent Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000011260 co-administration Methods 0.000 abstract 3
- 230000009385 viral infection Effects 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 230000009897 systematic effect Effects 0.000 abstract 2
- 230000004087 circulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003253 viricidal effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método de terapia farmacéutica que comprende la co-administración de cualquier forma de interferón o cualquier derivado del mismo con una dosis baja de ribavirina (inferior a 400 mg/día o inferior a 6 mg/kg/día, o compuesto relacionado, donde la ribavirina o compuesto relacionado provee un nivel de sangre clínicamente efectivo en la circulación portal pero un nivel de sangre menos del clínicamente efectivo en la circulación periférica, para proveer de este modo un efecto sistemático de interferón a través de todo el cuerpo pero un efecto selectivo de ribavirina en el hígado. El método provee además para la co-administración de cualquier forma de interferón o cualquier derivado del mismo con una dosis elevada de ribavirina (preferentemente desde 400-800 mg/día), o compuesto relacionado, donde la ribavirina o compuesto relacionado se administra como una formulación de liberación lenta tal que la misma provee además una respuesta virológica sostenida en un paciente y efectos secundarios reducidos. El método provee asimismo para la co-administración de un antioxidante u otro agente protector de membrana con tanto el interferón como la ribavirina tal que la actividad hepatoprotectora del antioxidante u otro agente protector de membranas complementa el efecto virucidal del interferón y ribavirina. El antioxidante u otro agente protector de membrana se puede administrar como una formulación sistemática o como una formulación hepático-selectiva de baja dosis y de liberación lenta. Reivindicación 32: El uso de una cantidad terapéuticamente efectiva de interferón con una dosis baja de ribavirina y opcionalmente un antioxidante u otro agente protector de membrana en la preparación de un medicamento para tratar infecciones virales en un paciente. Reivindicación 33: Un kit para uso en el tratamiento de infecciones virales caracterizado porque comprende una cantidad terapéuticamente efectiva de interferón en combinación con ribavirina y opcionalmente un antioxidante u otro agente protector de membrana como una formulación de liberación lenta. Reivindicación 43: Una composición farmacéutica para el tratamiento de infecciones virales en un paciente caracterizado porque comprende una cantidad terapéuticamente efectiva de interferón conjuntamente con una dosis baja de ribavirina y opcionalmente un antioxidante u otro agente protector de membrana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49482803P | 2003-08-13 | 2003-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045263A1 true AR045263A1 (es) | 2005-10-19 |
Family
ID=34193246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102894A AR045263A1 (es) | 2003-08-13 | 2004-08-12 | Metodo, kit y composicion farmaceutica para tratar infecciones virales |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070202078A1 (es) |
| EP (1) | EP1660116A4 (es) |
| JP (1) | JP2007501806A (es) |
| CN (1) | CN1835765A (es) |
| AR (1) | AR045263A1 (es) |
| AU (1) | AU2004264255A1 (es) |
| BR (1) | BRPI0413474A (es) |
| CA (1) | CA2535451A1 (es) |
| CL (1) | CL2004002030A1 (es) |
| IL (1) | IL173630A0 (es) |
| NO (1) | NO20060651L (es) |
| NZ (1) | NZ545159A (es) |
| RU (1) | RU2371195C2 (es) |
| WO (1) | WO2005016370A1 (es) |
| ZA (1) | ZA200601181B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| JP4732696B2 (ja) | 2002-04-09 | 2011-07-27 | フラメル・テクノロジー | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
| WO2006131790A2 (en) * | 2005-06-09 | 2006-12-14 | Flamel Technologies | Oral ribavirin pharmaceutical composition |
| CN105521485A (zh) * | 2007-09-05 | 2016-04-27 | 尼古拉·叶夫根尼耶维奇·沙图诺夫斯基 | 脱铁乳铁蛋白组合物及其用于治疗病毒性丙型肝炎的方法 |
| WO2009046369A2 (en) * | 2007-10-05 | 2009-04-09 | Medtronic, Inc. | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| KR20120106942A (ko) | 2009-10-30 | 2012-09-27 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법 |
| AU2011330701A1 (en) | 2010-11-19 | 2013-07-04 | Venus Remedies Limited | Novel conjugates for targeted drug delivery |
| RU2665638C1 (ru) * | 2017-05-24 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3222259A (en) * | 1963-10-25 | 1965-12-07 | Ethyl Corp | Flare stack with a liquid seal |
| JPS5439143Y2 (es) * | 1976-04-16 | 1979-11-20 | ||
| US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| PT903148E (pt) * | 1997-09-21 | 2002-02-28 | Schering Corp | Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| DE69901321T2 (de) * | 1998-05-15 | 2002-12-12 | Schering Corp., Kenilworth | Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| RU2001113268A (ru) * | 1998-10-16 | 2003-09-27 | Шеринг Корпорейшн (US) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с |
| CA2354536A1 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| JP2002535353A (ja) * | 1999-01-29 | 2002-10-22 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | 医薬品組成物 |
| CN1355708A (zh) * | 1999-04-19 | 2002-06-26 | 先灵公司 | 包含利巴韦林与抗氧化剂的hcv联合治疗 |
| US6924270B2 (en) * | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU2002213343A1 (en) * | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| PL369129A1 (en) * | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
| CA2372987A1 (en) * | 2001-12-11 | 2003-06-11 | Thomas R. Wiseman | Method of disposal of liquid from gas wells |
-
2004
- 2004-08-03 CN CNA200480023166XA patent/CN1835765A/zh active Pending
- 2004-08-03 JP JP2006522842A patent/JP2007501806A/ja active Pending
- 2004-08-03 CA CA002535451A patent/CA2535451A1/en not_active Abandoned
- 2004-08-03 WO PCT/AU2004/001031 patent/WO2005016370A1/en not_active Ceased
- 2004-08-03 AU AU2004264255A patent/AU2004264255A1/en not_active Abandoned
- 2004-08-03 ZA ZA200601181A patent/ZA200601181B/en unknown
- 2004-08-03 NZ NZ545159A patent/NZ545159A/en unknown
- 2004-08-03 BR BRPI0413474-5A patent/BRPI0413474A/pt not_active IP Right Cessation
- 2004-08-03 RU RU2006107566/15A patent/RU2371195C2/ru not_active IP Right Cessation
- 2004-08-03 EP EP04737647A patent/EP1660116A4/en not_active Ceased
- 2004-08-03 US US10/568,176 patent/US20070202078A1/en not_active Abandoned
- 2004-08-09 CL CL200402030A patent/CL2004002030A1/es unknown
- 2004-08-12 AR ARP040102894A patent/AR045263A1/es unknown
-
2006
- 2006-02-09 NO NO20060651A patent/NO20060651L/no not_active Application Discontinuation
- 2006-02-09 IL IL173630A patent/IL173630A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200601181B (en) | 2007-04-25 |
| RU2371195C2 (ru) | 2009-10-27 |
| EP1660116A4 (en) | 2008-04-30 |
| NO20060651L (no) | 2006-05-02 |
| JP2007501806A (ja) | 2007-02-01 |
| CA2535451A1 (en) | 2005-02-24 |
| US20070202078A1 (en) | 2007-08-30 |
| WO2005016370A1 (en) | 2005-02-24 |
| IL173630A0 (en) | 2006-07-05 |
| RU2006107566A (ru) | 2007-09-20 |
| BRPI0413474A (pt) | 2006-10-17 |
| CN1835765A (zh) | 2006-09-20 |
| CL2004002030A1 (es) | 2005-06-03 |
| NZ545159A (en) | 2009-03-31 |
| AU2004264255A1 (en) | 2005-02-24 |
| EP1660116A1 (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| WO2004002999A8 (en) | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| BRPI0412426A (pt) | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente | |
| JP2005501110A5 (es) | ||
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| BR0313117A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
| WO2003049694A3 (en) | Methods of therapy for non-hodgkin's lymphoma | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| BRPI0413474A (pt) | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais | |
| JP2003528919A5 (es) | ||
| AR045070A1 (es) | Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| CO5241355A1 (es) | Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis | |
| MX9304197A (es) | Nuevo uso de dimero de lisozina y composiciones que lo contienen. | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |